EC approves Merck’s Keytruda and chemotherapy combination for TNBC patients
The European Commission (EC) has approved Merck’s Keytruda (pembrolizumab) plus chemotherapy combination to treat triple-negative breast cancer (TNBC) patients. Keytruda, an anti-programmed death receptor-1 (PD-1) therapy, blocks the